Axogen, Inc. - Common Stock (AXGN)

AxoGen (NASDAQ:AXGN) reported third-quarter revenue growth of 26.2% as demand for its nerve-repair products increased across its breast, extremities, oral and maxillofacial, and head-and-neck markets. The company also raised its full-year revenue outlook following the October acquisition of BioCircu

Breast segment surged 60% while BioCircuit acquisition expands nerve repair market reach.

Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.

Breast segment revenue surged over 50% year over year, driving accelerated growth.

AxoGen (NASDAQ:AXGN) reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target markets. The company raised its full-year revenue outlook to at least $279 million, representing gr

AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified. Speaking during a company event, Dale said he w

Axogen (AXGN) Q3 2025 Earnings Transcript

Axogen (AXGN) Q1 2025 Earnings Transcript

This healthcare firm develops nerve repair solutions for hospitals and specialists in the U.S. and select global markets.

Axogen (AXGN) Q2 2025 Earnings Transcript

This surgical solutions provider for nerve repair reported a notable insider sale amid a year of strong share price gains.

This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.

Axogen (AXGN) Q4 2025 Earnings Call Transcript

This healthcare firm delivers surgical solutions for peripheral nerve repair, targeting specialized surgeons across U.S. and global markets.

The CEO of this innovative nerve regeneration company sold thousands of shares in December 2025, among multiple other insiders at the company who sold shares to close out that year.